Assoziation von sehr niedrigen PSA-Werten mit dem Auftreten von Metastasen und h��herer Mortalit��t bei Patienten mit Gleason Score 8���10 Prostatakrebs

Autor: Abrams-Pompe, RS, Preisser, F, Graefen, M, Huland, H, Meyer, C, Tilki, D

Publikováno v: 67. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie; 20220407-20220408; Münster; DOCV 2.1 /20220301/

Einleitung: Sehr niedrige PSA-Werte bei Patienten mit high-risk Prostatakrebs (PCa) k��nnen ein Zeichen f��r Dedifferenzierung und konsekutiv vergesellschaftet mit schlechter Prognose sein. Methoden: Retrospektive Analyse von 3.010 Patienten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5a25391baeb11fd8667756ec42932e

European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.

Autor: Preisser F; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany., Abrams-Pompe RS; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Stelwagen PJ; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Böhmer D; Department of Radiation Oncology, Charité University Hospital, Berlin, Germany., Zattoni F; Department of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy., Magli A; Department of Radiation Oncology, University Hospital of Udine, ASUIUD, Udine, Italy; Department of Radiation Oncology, Hospital San Martino, Belluno, Italy., Rivas JG; Department of Urology, Clinico San Carlos Hospital, Madrid, Spain., Dilme RV; Department of Urology, Clinico San Carlos Hospital, Madrid, Spain., Sepulcri M; Radiation Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Eguibar A; Department of Urology, La Paz University Hospital, Madrid, Spain., Heidegger I; Department of Urology, Medical University Innsbruck, Innsbruck, Austria., Arnold C; Department of Therapeutic Radiology and Oncology, Medical University Innsbruck, Innsbruck, Austria., Fankhauser CD; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, University Zurich, Zurich, Switzerland., Chun FK; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany., van der Poel H; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Gandaglia G; Department of Urology, Urological Research Institute, Vita-Salute University and San Raffaele Hospital, Milan, Italy., Wiegel T; Department of Radiotherapy and Radiooncology, University Hospital Ulm, Ulm, Germany., van den Bergh RCN; Department of Urology, Antonius Hospital, Utrecht, The Netherlands., Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey. Electronic address: d.tilki@uke.de.

Publikováno v: European urology [Eur Urol] 2024 Feb; Vol. 85 (2), pp. 164-170. Date of Electronic Publication: 2023 Jun 22.

Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy.

Autor: Preisser F; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany., Wang N; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany., Abrams-Pompe RS; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Chun FK; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany., Graefen M; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany., Huland H; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany., Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: d.tilki@uke.de.

Publikováno v: Urologic oncology [Urol Oncol] 2022 Apr; Vol. 40 (4), pp. 161.e9-161.e14. Date of Electronic Publication: 2021 Dec 30.

The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.

Autor: Abrams-Pompe RS; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: rapompe@gmail.com., Fanti S; Department of Nuclear Medicine, Policlinico S. Orsola, University of Bologna, Bologna, Italy., Schoots IG; Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Moore CM; Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, UCLH NHS Foundation Trust, London, UK., Turkbey B; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vickers AJ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Walz J; Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France., Steuber T; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Eastham JA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Publikováno v: European urology oncology [Eur Urol Oncol] 2021 Jun; Vol. 4 (3), pp. 370-395. Date of Electronic Publication: 2020 Dec 04.